ATE424206T1 - Kombination aus n-(3-methoxy-5-methylpyrazin-2- yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3 sulfonamid und einem biphosphonat - Google Patents

Kombination aus n-(3-methoxy-5-methylpyrazin-2- yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3 sulfonamid und einem biphosphonat

Info

Publication number
ATE424206T1
ATE424206T1 AT04768282T AT04768282T ATE424206T1 AT E424206 T1 ATE424206 T1 AT E424206T1 AT 04768282 T AT04768282 T AT 04768282T AT 04768282 T AT04768282 T AT 04768282T AT E424206 T1 ATE424206 T1 AT E424206T1
Authority
AT
Austria
Prior art keywords
yluphenyl
biphosphonate
methylpyrazine
oxadiazole
sulfonamide
Prior art date
Application number
AT04768282T
Other languages
English (en)
Inventor
Neil Gallagher
Jon Owen Curwen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29226541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE424206(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE424206T1 publication Critical patent/ATE424206T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04768282T 2003-09-05 2004-09-02 Kombination aus n-(3-methoxy-5-methylpyrazin-2- yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3 sulfonamid und einem biphosphonat ATE424206T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0320806.3A GB0320806D0 (en) 2003-09-05 2003-09-05 Therapeutic treatment

Publications (1)

Publication Number Publication Date
ATE424206T1 true ATE424206T1 (de) 2009-03-15

Family

ID=29226541

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768282T ATE424206T1 (de) 2003-09-05 2004-09-02 Kombination aus n-(3-methoxy-5-methylpyrazin-2- yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3 sulfonamid und einem biphosphonat

Country Status (30)

Country Link
US (2) US20060287241A1 (de)
EP (2) EP2018865A3 (de)
JP (1) JP2007504265A (de)
KR (1) KR20060069857A (de)
CN (1) CN1878555A (de)
AR (1) AR045572A1 (de)
AT (1) ATE424206T1 (de)
AU (1) AU2004269956B2 (de)
BR (1) BRPI0413974A (de)
CA (1) CA2537096A1 (de)
CO (1) CO5650255A2 (de)
CY (1) CY1110315T1 (de)
DE (1) DE602004019795D1 (de)
DK (1) DK1663236T3 (de)
ES (1) ES2321620T3 (de)
GB (1) GB0320806D0 (de)
HK (1) HK1090294A1 (de)
HR (1) HRP20090229T1 (de)
IL (1) IL173817A (de)
IS (1) IS8365A (de)
MX (1) MXPA06002485A (de)
NO (1) NO20061051L (de)
NZ (1) NZ545468A (de)
PL (1) PL1663236T3 (de)
PT (1) PT1663236E (de)
RU (1) RU2398588C2 (de)
SI (1) SI1663236T1 (de)
TW (1) TW200509934A (de)
WO (1) WO2005023264A1 (de)
ZA (1) ZA200601871B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
ES2377426T3 (es) 2007-10-12 2012-03-27 Astrazeneca Ab Composición de zibotentán que contiene manitol y celulosa microcristalina
BRPI0906404B8 (pt) 2008-01-24 2021-05-25 Univ Louisiana State construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno
EP4035685A1 (de) 2012-10-30 2022-08-03 Esperance Pharmaceuticals, Inc. Antikörper-wirkstoff-konjugate und verfahren zur verwendung
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) * 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4234571A (en) 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4431635A (en) 1979-06-13 1984-02-14 Coy David Howard LH-RH Antagonists
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4547370A (en) 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US5003011A (en) 1985-04-09 1991-03-26 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4801577A (en) 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4851385A (en) 1987-07-15 1989-07-25 Indiana University Foundation LHRH antagonist analogs having low histamine-release activity
US4935491A (en) 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5300492A (en) 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
US4992421A (en) 1988-04-19 1991-02-12 Abbott Laboratories Luteinizing hormone releasing hormone antagonist
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
US5668254A (en) 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5171635A (en) 1990-10-10 1992-12-15 E. I. Du Pont De Nemours And Company Composite wire construction
US5371070A (en) 1992-11-09 1994-12-06 The Salk Institute For Biological Studies Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins
US5413990A (en) 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
WO1997014697A1 (en) 1995-10-19 1997-04-24 Takeda Chemical Industries, Ltd. Thienopyridine derivatives as gonadotropin releasing hormone antagonists
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0100566D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
JP2004528340A (ja) * 2001-05-02 2004-09-16 ノバルティス アクチエンゲゼルシャフト ビスホスホネートの医薬的使用
SE0101692D0 (sv) 2001-05-14 2001-05-14 Astrazeneca Ab Compounds
ATE498408T1 (de) * 2001-08-10 2011-03-15 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment

Also Published As

Publication number Publication date
HRP20090229T1 (en) 2009-05-31
DK1663236T3 (da) 2009-05-25
GB0320806D0 (en) 2003-10-08
AR045572A1 (es) 2005-11-02
NZ545468A (en) 2009-03-31
EP1663236B1 (de) 2009-03-04
KR20060069857A (ko) 2006-06-22
MXPA06002485A (es) 2006-06-20
IS8365A (is) 2006-03-20
CO5650255A2 (es) 2006-06-30
DE602004019795D1 (de) 2009-04-16
IL173817A0 (en) 2006-07-05
ES2321620T3 (es) 2009-06-09
PL1663236T3 (pl) 2009-07-31
EP1663236A1 (de) 2006-06-07
HK1090294A1 (en) 2006-12-22
US20060287241A1 (en) 2006-12-21
RU2006110736A (ru) 2007-10-10
EP2018865A3 (de) 2009-11-18
ZA200601871B (en) 2007-05-30
EP2018865A2 (de) 2009-01-28
NO20061051L (no) 2006-04-03
US20100004181A1 (en) 2010-01-07
PT1663236E (pt) 2009-04-24
TW200509934A (en) 2005-03-16
IL173817A (en) 2011-03-31
WO2005023264A1 (en) 2005-03-17
BRPI0413974A (pt) 2006-10-31
AU2004269956A1 (en) 2005-03-17
RU2398588C2 (ru) 2010-09-10
CA2537096A1 (en) 2005-03-17
SI1663236T1 (sl) 2009-06-30
CN1878555A (zh) 2006-12-13
CY1110315T1 (el) 2015-01-14
JP2007504265A (ja) 2007-03-01
AU2004269956B2 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
ATE424206T1 (de) Kombination aus n-(3-methoxy-5-methylpyrazin-2- yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3 sulfonamid und einem biphosphonat
DE60218084D1 (de) Markierungspartikel
DK1368446T3 (da) Basisoliesammensætning
IS8307A (is) Fenýl eða pýridýl amíð efnasambönd sem prostaglandín E2 mótlyf
DE60224724D1 (de) 3,4-alkylendioxythiophen-verbindungen und ihre polymere
DE60141385D1 (de) Hybride Bluetooth/RFID basierte Echtzeit-Positionsbestimmung
DE60216854D1 (de) Polyamid-Zusammensetzung
IS8273A (is) Nýr búnaður
ITMI20011061A0 (it) Composizioni fluoroelastomeriche
EE200400075A (et) Peroraalsed antidiabeetilised ained
ITMI20011060A0 (it) Composizioni fluoroelastomeriche
NO20034695D0 (no) Nye sammensetninger
NO20034949L (no) Sulfonamider
ITTO20040744A1 (it) Dispositivo di filtro dell'aria.
FIU20020421U0 (fi) Raseeminen tamsulosiinivapaa emäs
DE60222693D1 (de) Nk1-antagonisten
ITTO20020789A1 (it) Formulazione solida
NO20042083L (no) Lineaere basiske forbindelser som har NK-2 antagonistaktivitet og formuleringer derav
NO20020102L (no) Formasjonsresistivitetsmåling som eliminerer effektene fra lateral verktöybevegelse
ITTO20020646A1 (it) Dispositivo per la filtrazione dell'aria
BR0310113B1 (pt) Composições pesticidas
DE60210813D1 (de) Zahnbürste
NO20024625L (no) Robotspill
DE60220235D1 (de) Optimierte teilchenförmige Zusammensetzungen
FR2838339B1 (fr) Derives poly-phosphonates pour compositions dentifrices

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1663236

Country of ref document: EP